Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.

Biolchi A, Tomei S, Santini L, Welsch JA, Toneatto D, Gaitatzis N, Bai X, Borrow R, Giuliani MM, Mori E, Pizza M.

Hum Vaccin Immunother. 2019;15(3):725-731. doi: 10.1080/21645515.2018.1537756. Epub 2019 Jan 2.

2.

Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study.

Welsch JA, Senders S, Essink B, Klein T, Smolenov I, Pedotti P, Barbi S, Verma B, Toneatto D.

Vaccine. 2018 Aug 23;36(35):5309-5317. doi: 10.1016/j.vaccine.2018.07.016. Epub 2018 Jul 27.

3.

Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.

Szenborn L, Block SL, Jackowska T, Konior R, D'Agostino D, Smolenov I, Toneatto D, Welsch JA.

Pediatr Infect Dis J. 2018 May;37(5):475-482. doi: 10.1097/INF.0000000000001896.

PMID:
29329168
4.

Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.

Baxter R, Keshavan P, Welsch JA, Han L, Smolenov I.

Hum Vaccin Immunother. 2016 May 3;12(5):1300-10. doi: 10.1080/21645515.2015.1136040. Epub 2016 Feb 1. Review.

5.

Serum bactericidal antibody assays - The role of complement in infection and immunity.

McIntosh ED, Bröker M, Wassil J, Welsch JA, Borrow R.

Vaccine. 2015 Aug 26;33(36):4414-21. doi: 10.1016/j.vaccine.2015.07.019. Epub 2015 Jul 15. Review.

PMID:
26187262
6.

Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.

Lee HJ, Chung MH, Kim WJ, Hong YJ, Choi KM, Lee J, Oh CE, Welsch JA, Kim KH, Hong KB, Dagnew AF, Bock H, Dull PM, Odrljin T.

Int J Infect Dis. 2014 Nov;28:204-10. doi: 10.1016/j.ijid.2014.06.008. Epub 2014 Oct 12.

7.

Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.

Gill CJ, Ram S, Welsch JA, Detora L, Anemona A.

Vaccine. 2011 Dec 9;30(1):29-34. doi: 10.1016/j.vaccine.2011.10.068. Epub 2011 Nov 7.

8.

Factor H and neisserial pathogenesis.

Welsch JA, Ram S.

Vaccine. 2008 Dec 30;26 Suppl 8:I40-5. Review.

9.

Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.

Plested JS, Welsch JA, Granoff DM.

Clin Vaccine Immunol. 2009 Jun;16(6):785-91. doi: 10.1128/CVI.00007-09. Epub 2009 Apr 1.

10.

Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa.

Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM.

J Infect Dis. 2009 May 1;199(9):1360-8. doi: 10.1086/597806.

11.

Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Granoff DM, Welsch JA, Ram S.

Infect Immun. 2009 Feb;77(2):764-9. doi: 10.1128/IAI.01191-08. Epub 2008 Dec 1.

12.

Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein.

Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM.

Infect Immun. 2008 Sep;76(9):4232-40. doi: 10.1128/IAI.00367-08. Epub 2008 Jun 30.

13.

Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen.

Welsch JA, Ram S, Koeberling O, Granoff DM.

J Infect Dis. 2008 Apr 1;197(7):1053-61. doi: 10.1086/528994.

PMID:
18419542
14.

Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody.

Welsch JA, Granoff D.

Clin Vaccine Immunol. 2007 Dec;14(12):1596-602. Epub 2007 Oct 3.

15.
16.

A universal vaccine for serogroup B meningococcus.

Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M.

Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10834-9. Epub 2006 Jul 6.

17.

The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance.

Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S.

J Immunol. 2006 Jul 1;177(1):501-10.

18.

Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870.

Koeberling O, Welsch JA, Granoff DM.

Vaccine. 2007 Feb 26;25(10):1912-20. Epub 2006 Apr 21.

PMID:
16677743
19.

Role of FNR and FNR-regulated, sugar fermentation genes in Neisseria meningitidis infection.

Bartolini E, Frigimelica E, Giovinazzi S, Galli G, Shaik Y, Genco C, Welsch JA, Granoff DM, Grandi G, Grifantini R.

Mol Microbiol. 2006 May;60(4):963-72.

20.

Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.

Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM.

J Infect Dis. 2006 Mar 15;193(6):821-8. Epub 2006 Feb 8.

PMID:
16479517
21.
22.
25.
26.
27.

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870.

Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, Serruto D, Litt D, Kroll S, Welsch JA, Granoff DM, Rappuoli R, Pizza M.

J Exp Med. 2003 Mar 17;197(6):789-99.

28.

Cellular and molecular events in a newly organizing lateral root meristem.

Sussex IM, Godoy JA, Kerk NM, Laskowski MJ, Nusbaum HC, Welsch JA, Williams ME.

Philos Trans R Soc Lond B Biol Sci. 1995 Oct 30;350(1331):39-43. Review.

PMID:
8577848
29.
30.

Transformation of Neurospora crassa by an integrative transforming plasmid is not enhanced by ribosomal DNA sequences.

Russell PJ, Welsch JA, Wagner S.

Biochim Biophys Acta. 1989 Jul 7;1008(2):243-6.

PMID:
2525404
31.

Different levels of DNA methylation in yeast and mycelial forms of Candida albicans.

Russell PJ, Welsch JA, Rachlin EM, McCloskey JA.

J Bacteriol. 1987 Sep;169(9):4393-5.

32.

Methods for DNA extraction from Candida albicans.

Glee PM, Russell PJ, Welsch JA, Pratt JC, Cutler JE.

Anal Biochem. 1987 Jul;164(1):207-13.

PMID:
2823631
33.

Intercondylar T-fractures.

Bryan RS, Welsch JA, Johnson EW Jr.

Minn Med. 1972 Oct;55(10):939-43. No abstract available.

PMID:
5074913
34.

Femoral shortening for leg-length discrepancy.

Welsch JA, Sweeting RC, Janes JM.

Mayo Clin Proc. 1971 Jan;46(1):29-36. No abstract available.

PMID:
5100987

Supplemental Content

Loading ...
Support Center